

## Cadmium and Zinc in the Aetiology of Inflammatory Arthritis

Abbas H. Khalaf<sup>1</sup>, Yasir A. Abdul-Nabi<sup>2</sup>, and Qassim H. Khalaf<sup>3</sup>

<sup>1-3</sup>Al-Qurna General Hospital, Basrah Health Directorate, Ministry of Health, Iraq.

Corresponding Author Email: \* [abasalshahin66@gmail.com](mailto:abasalshahin66@gmail.com), [yasiradnan1977@gmail.com](mailto:yasiradnan1977@gmail.com),  
[alshaheen.qassim@gmail.com](mailto:alshaheen.qassim@gmail.com)

### ABSTRACT

**Background:** Autoimmune diseases is observed globally, with rheumatic diseases being the most prevalent among them. Cd and Zn have their role in autoimmune diseases. **Objectives:** To investigate the role of cadmium (Cd) and zinc (Zn) in rheumatoid arthritis (RA) pathogenesis by comparing their serum levels in RA patients to healthy controls. **Materials and Methods:** Biochemical studies were conducted to measure Zn and Cd levels using atomic absorption spectrophotometry and evaluate rheumatoid factor & anti-CCP levels with ELISA. **Results:** Patient demographics showed no significant differences in sex, age, and smoking status between RA patients (n=50) and controls (n=50). Serum Zn levels were lower in RA patients ( $0.66 \pm 0.08 \mu\text{g/L}$ ) compared to controls ( $0.72 \pm 0.11 \mu\text{g/L}$ ;  $p=0.017$ ), Serum Cd levels were higher in RA patients ( $0.99 \pm 0.28 \text{ ng/L}$ ) compared to controls ( $0.89 \pm 0.21 \text{ ng/L}$ ;  $p=0.031$ ). **Conclusion:** The study suggests an association between elevated serum cadmium and reduced serum zinc levels in RA patients, emphasizing the need for further research on environmental factors and autoimmune disease.

**Keywords:** Cadmium, Zinc, Autoimmune Diseases, and Inflammatory Arthritis.

### Article Information

Received: April 05, 2026; Revised: April 20, 2026; Online: June 2026

## INTRODUCTION

There has been a steady raise in the prevalence of autoimmune diseases over the world, particularly in the developed, industrialized western and northern countries. Rheumatic diseases is rising the most Among autoimmune diseases, followed by endocrine and gastrointestinal diseases.[1]. In daily clinical practice rheumatic diseases are an important issue where patients potentially suffer from severe chronic pain, joint damage, increasing disability, early retirement and even death [2] The three most common types of inflammatory arthritis (IA) are rheumatoid arthritis (RA) affects about 1%, psoriatic arthritis (PsA), and ankylosing spondylitis(AS). These are chronic, progressive autoimmune diseases whose pathogenesis is still not fully understood [3][4].

Inflammatory pathway for these diseases is the activation of T helper cells 17 (Th17), resulting in an increase in pro-inflammatory cytokines, tumour necrosis factor (TNF- $\alpha$ ),

and the joint inflammation process [5][6]. Genetic factors play an essential role in autoimmunity, but they do not explain all the differences in IA prevalence among populations [7]. As in many other disorders, unfavourable genetic factors are brought forth in specific environmental conditions. Inflammation and various environmental contaminants (immune adjuvants, immunotoxic substances) can induce or exacerbate autoimmunity. Numerous factors have been investigated in association with IA risk, including smoking, diet, physical activity, vitamin D deficiency, alcohol use, medications, and infections [8]. It is considered that tobacco smoking is significantly associated with RA and PsA risk in the general population; in turn, its impact on AS is linked mainly to disease progression [9] [10].The influence of smoking on the autoimmune process has been explained by several hypotheses, involving such factors as increased oxidative stress, general inflammation, and triggering autoantibody

production [9][11][12]. As there is a well-documented link between cigarette smoking and arthritis, a growing interest also has been observed in the role of different environmental pollutants (especially cadmium compounds) in rheumatic diseases [13][14].

Cadmium is a major public health concern, as it is widespread and toxic and contributes to the development of numerous diseases [15], [16]. Both in work settings and in daily life, there are many potential sources of cadmium, such as smoking (including passive smoking), vehicle exhaust, low emissions from coal-fired furnaces, recycling of electronic waste, the manufacture of nickel-cadmium batteries, industry (dyeing, textiles, plastics, mining...), as well as cosmetics or contaminated food [17][18]. The link between cadmium and IA however is not clear, having been studied mainly in patients with RA. A Korean cross-sectional study of 53,829 residents found a significant positive association between serum cadmium levels and the incidence of RA [19]. Similar relationships have been observed by other authors [20][21][22]. There is evidence that exposure to metals (including cadmium) may cause autoimmunity and epigenetic effects, thereby contributing to the incidence and prevalence of autoimmune diseases [23][24]. Some metal compounds modify cytokine production, leading to an imbalance between CD4 Th1 and Th2 cell activation and altering the pro- and anti-inflammatory cytokine profiles. This immune dysregulation can result in impaired cell-mediated immunity and /or aberrant humoral immunity, and, consequently, an autoimmune disease [23]. The influence of cadmium on the development of IA may, therefore, be related to the toxic effect on the immune system and its dysregulation, this impact on the development of IA can be linked to an anti-pro-oxidative imbalance and the subsequent induction of oxidative stress and inflammatory processes [25].

Also, Cadmium inhibits absorption of iron by the suppression of iron transport in duodenal enterocytes [26]. Iron deficiency and anaemia of chronic disease are often found in patients with autoimmune diseases and chronic inflammation (including joint diseases) [27]. These conditions increase cadmium absorption and accumulation in the body [26]. Low haemoglobin levels are associated with disease activity, joint damage, pain, and functional impairment; they may predict worse outcomes in RA patients [28].

Low zinc levels in the blood are reported in patients with RA. Zinc is a cofactor for more than 3000 proteins and, as a signalling ion, affects many pathways relevant to joint disease [29].

Cadmium absorption increases under zinc deficiency conditions, similar to iron. Cadmium dust inhalation can cause macrophage activation, inflammation, and IA development [30][31] conclude that a genetic variation in zinc transporters influences blood cadmium concentrations (Cd-B), individuals with a certain genotype of these transporters have higher Cd-B. It seems likely that people with this genetic condition are more susceptible to developing the diseases to which cadmium exposure may contribute. Zn is a crucial element in a series of cellular functions as normal growth, protein metabolism, membrane stability, and metalloenzyme functions [32]. Zn, has several other effects on immune response, complement system, lysosomal enzyme release, and macrophage functions [33]. Zn is also indispensable in many steps of the inflammatory reactions. Among these are prostaglandin biosynthesis, stimulation of lymphocytes and immune response, and scavenging of toxic free oxygen radicals [34][35] Zn is likewise an important element in collagen tissue formation and bone metabolism [36]

## Aim of study

This study aimed to explore the possible role of Cd and Zn in the pathogenesis of rheumatoid arthritis (RA) by comparing serum levels of these elements in patients with RA to those individuals without the RA.

## MATERIALS AND METHODS

### Biochemical studies

#### Determination of Zn levels

The serum levels of Zn were determined at the Chemical Analysis by flameless atomic absorption spectrophotometry using an atomic absorption spectrophotometer (Shimadzu, GFA-7000f, Japan).

Zn was measured at wavelength 213.9 nm using a slit width of 0.5 nm and lamp current 5 mA. The levels of Zn were gained by extrapolation of the criterion curve followed by multiplication with the dilution Factor.

#### Determination of Cd levels

The serum levels of Cd were determined at the Chemical Analysis by flameless atomic absorption spectrophotometry using an atomic

absorption spectrophotometer (Shimadzu, GFA-7000f, Japan).

Cd was measured at wavelength 228.8 nm using a slit width of 0.7 nm and lamp current 8 mA. The levels of Cd were gained by extrapolation of the criterion curve followed by multiplication with the dilution Factor.

### Rheumatoid factor & Anti-CCP

Rheumatoid factor & Anti-CCP hs<sup>®</sup> (high sensitive) is an ELISA-based, automated, in-vitro test system for the quantitative determination of IgG antibodies against cyclic citrullinated peptides (CCP) in human serum or plasma.

### Statistical Analysis

Quantitative variables were expressed as means  $\pm$  standard deviation. Parametric data were analysed by the t-test, while the Mann–Whitney U test was applied for non-parametric data. Correlations between disease and cadmium and zinc levels. All statistical analyses were conducted with the SPSS v26. Statistical significance was set at  $p < 0.05$ .

## RESULTS

**Table (1)** shows a non- significant difference in sex, age and smoking between OA patients and control groups.

**Table (1): Described and the demographic characteristics in the OA patients and control groups.**

| Variable  |            | Patients(OA)<br>(n=50) | Controls<br>(n=50) | P.value |
|-----------|------------|------------------------|--------------------|---------|
| Sex       | Male       | 38                     | 37                 | 0.818   |
|           | Female     | 12                     | 13                 |         |
| Smoking   | Smoker     | 25                     | 17                 | 0.107   |
|           | Non-smoker | 25                     | 33                 |         |
| Age(year) |            | Mean $\pm$ SD          | Mean $\pm$ SD      | 0.32    |
|           |            | 42.88 $\pm$ 14.22      | 44.81 $\pm$ 13.33  |         |

In comparing the mean levels of Zn, Cd & Anti ccp between the control group and RA patients, Zn levels were decreased in the RA group ( $0.66 \pm 0.08 \mu\text{g/L}$ ) compared to ( $0.72 \pm 0.11 \mu\text{g/L}$ ) in the control group (P.value = 0.017). while increase in levels of Cd & Anti ccp ( $0.99 \pm 0.28 \text{ ng/L}$ ) & ( $84.40 \pm 53.17 \text{ U/ml}$ ) in RA group compared to ( $0.89 \pm 0.21 \text{ ng/L}$ ) & ( $13.64 \pm 4.55 \text{ U/ml}$ ) in control group (P.value = 0.031, 0.001) respectively, Table 2.

**Table (2): Relationship of Zn, Cd & Anti ccp with OA patients and controls.**

| Parameters | Patients<br>(n=50) Mean $\pm$ SD | Controls<br>(n=50) Mean $\pm$ SD | P.value |
|------------|----------------------------------|----------------------------------|---------|
| Zinc       | 0.66 $\pm$ 0.08                  | 0.72 $\pm$ 0.11                  | 0.017   |
| Cadmium    | 0.99 $\pm$ 0.28                  | 0.89 $\pm$ 0.21                  | 0.031   |
| Anti ccp   | 84.40 $\pm$ 53.17                | 13.64 $\pm$ 4.55                 | 0.001   |

## DISCUSSION

We noticed the non- significant statistical differences in sex, age and smoking between OA patients and control groups.as in table (1). But ,we observed that Zn levels were decreased in patients with RA compared to non-RA individuals (0.66 + 0.08 vs 0.72 + 0.11) and p value (0.017) while there were increase in Cd levels in RA patient in compare with non RA individuals (0.99 + 0.28vs0.89 + 0.21) and p value(0.031). Previous reports have indicated that the serum zinc concentration is lower in patients with RA than in healthy individuals [37] .Zinc has a major influence on the inflammatory process which occurs in patients with rheumatoid arthritis, the enzyme superoxide dismutase which is often deficient in zinc , zinc is also required to improve the scavenger process of oxygen free radicals generated during phagocytosis by increasing the bioavailability of enzyme superoxide dismutase [38].So, the treatment with zinc supplements were suggested and optimizing the zinc supply along with other standard medications in order to reduce RA activity[39]. The results of decrease levels of Zn in RA patients were agree with those studies of Ullah et al [40] Ali H et al [41],Sahebari M et al [42]and Farid Y et al [43].

Our study showing that patients with RA have markedly elevated serum Cd levels compared with control group(0.99 + 0.28vs0.89 + 0.21) and p value(0.031). Cigarette smoking, which is an established risk

factor for RA[44] is also a source of cadmium exposure, with serum levels raised three-fold in current smokers [45], A few reports, higher concentrations of cadmium have been found in the blood, independent of smoking habits [46] .Nanoparticles of cadmium in dust and cigarette smoke are believed capable of inducing a lung process which could play a part in the initiation of RA; further, in a commonly used animal model of RA (collagen-induced arthritis), cadmium chloride in drinking water can potentially exacerbate some of the biological features that may occur during the disease's induction phase [47].

## CONCLUSION

The study suggests an association between elevated serum cadmium and reduced serum zinc levels in RA patients, emphasizing the need for further research on environmental factors and autoimmune disease.

## REFERENCES

- [1] A. Lerner, P. Jeremias, and T. Matthias, "The World Incidence and Prevalence of Autoimmune Diseases is Increasing," *International Journal of Celiac Disease*, Vol. 3, 2015, Pages 151-155, vol. 3, no. 4, pp. 151–155, Nov. 2015, doi: 10.12691/IJCD-3-4-8.
- [2] M. Al Maini *et al.*, "The global challenges and opportunities in the practice of rheumatology: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases," *Clin. Rheumatol.*, vol. 34, no. 5, pp.

819–829, May 2015, doi: 10.1007/s10067-014-2841-6.

[3] L. Scotti, M. Franchi, A. Marchesoni, and G. Corrao, “Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis,” *Semin. Arthritis Rheum.*, vol. 48, no. 1, pp. 28–34, Aug. 2018, doi: 10.1016/J.SEMARTHRT.2018.01.003.

[4] J. Zhao *et al.*, “Prevalence of ankylosing spondylitis in a Chinese population: a systematic review and meta-analysis,” *Rheumatology International* 2020 40:6, vol. 40, no. 6, pp. 859–872, Mar. 2020, doi: 10.1007/S00296-020-04537-0.

[5] D. G. McGonagle, I. B. McInnes, B. W. Kirkham, J. Sherlock, and R. Moots, “The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies,” *Ann. Rheum. Dis.*, vol. 78, no. 9, pp. 1167–1178, Sep. 2019, doi: 10.1136/ANNRHEUMDIS-2019-215356.

[6] D. Simone, M. H. Al Mossawi, and P. Bowness, “Progress in our understanding of the pathogenesis of ankylosing spondylitis,” *Rheumatology*, vol. 57, no. suppl\_6, pp. vi4–vi9, Nov. 2018, doi: 10.1093/RHEUMATOLOGY/KEY001.

[7] Y. Shapira, N. Agmon-Levin, and Y. Shoenfeld, “Geoepidemiology of autoimmune rheumatic diseases,” *Nature Reviews Rheumatology* 2010 6:8, vol. 6, no. 8, pp. 468–476, Jun. 2010, doi: 10.1038/nrrheum.2010.86.

[8] X. Jiang and L. Alfredsson, “Modifiable environmental exposure and risk of rheumatoid arthritis—current evidence from genetic studies,” *Arthritis Research & Therapy* 2020 22:1, vol. 22, no. 1, pp. 154–, Jun. 2020, doi: 10.1186/S13075-020-02253-5.

[9] U. S. D. T. Nguyen *et al.*, “Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: A populationbased study,” *Ann. Rheum. Dis.*, vol. 77, no. 1, pp. 119–123, Jan. 2018, doi: 10.1136/annrheumdis-2017-211625.

[10] “Effect of cigarette smoking and alcohol consumption on disease activity and physical functioning in ankylosing spondylitis: a cross-sectional study - PubMed.” Accessed: Feb. 18, 2026. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/26550348/>

[11] K. Chang, S. M. Yang, S. H. Kim, K. H. Han, S. J. Park, and J. Il Shin, “Smoking and Rheumatoid Arthritis,” *International Journal of Molecular Sciences* 2014, Vol. 15, Pages 22279–22295, vol. 15, no. 12, pp. 22279–22295, Dec. 2014, doi: 10.3390/IJMS15122279.

[12] M. Harel-Meir, Y. Sherer, and Y. Shoenfeld, “Tobacco smoking and autoimmune rheumatic diseases,” *Nature Clinical Practice Rheumatology* 2007 3:12, vol. 3, no. 12, pp. 707–715, Dec. 2007, doi: 10.1038/ncprheum0655.

[13] M. Essouma and J. J. N. Noubiap, “Is air pollution a risk factor for rheumatoid arthritis?,” *Journal of Inflammation* 2015 12:1, vol. 12, no. 1, pp. 48–, Jul. 2015, doi: 10.1186/S12950-015-0092-1.

[14] J. Shin, J. Lee, J. Lee, and E. H. Ha, “Association between Exposure to Ambient Air Pollution and Rheumatoid Arthritis in Adults,” *International Journal of Environmental Research and Public Health* 2019, Vol. 16, Page 1227, vol. 16, no. 7, p. 1227, Apr. 2019, doi: 10.3390/IJERPH16071227.

[15] M. Balali-Mood, K. Naseri, Z. Tahergorabi, M. R. Khazdair, and M. Sadeghi, “Toxic Mechanisms of Five Heavy Metals: Mercury, Lead, Chromium, Cadmium, and Arsenic,” *Front. Pharmacol.*, vol. 12, p. 643972, Apr. 2021, doi: 10.3389/fphar.2021.643972.

[16] W. H. Organization, “Preventing disease through healthy environments: exposure to cadmium: a major public health concern,” Oct. 28, 2019, *World Health Organization*. Accessed: Feb. 18, 2026.

- [Online]. Available: <https://iris.who.int/handle/10665/329480>
- [17] G. Genchi, M. S. Sinicropi, G. Lauria, A. Carocci, and A. Catalano, "The Effects of Cadmium Toxicity," *International Journal of Environmental Research and Public Health* 2020, Vol. 17, Page 3782, vol. 17, no. 11, p. 3782, May 2020, doi: 10.3390/IJERPH17113782.
- [18] M. T. Hayat, M. Nauman, N. Nazir, S. Ali, and N. Bangash, "Environmental Hazards of Cadmium: Past, Present, and Future," *Cadmium Toxicity and Tolerance in Plants: From Physiology to Remediation*, pp. 163–183, Dec. 2018, doi: 10.1016/B978-0-12-814864-8.00007-3.
- [19] S. H. Joo, J. Lee, D. Hutchinson, and Y. W. Song, "Prevalence of rheumatoid arthritis in relation to serum cadmium concentrations: cross-sectional study using Korean National Health and Nutrition Examination Survey (KNHANES) data," *BMJ Open*, vol. 9, no. 1, p. e023233, Jan. 2019, doi: 10.1136/BMJOPEN-2018-023233.
- [20] R. Cappelletti, M. Ceppi, J. Claudatus, and V. Gennaro, "Health status of male steel workers at an electric arc furnace (EAF) in Trentino, Italy," *Journal of Occupational Medicine and Toxicology* 2016 11:1, vol. 11, no. 1, pp. 7–, Feb. 2016, doi: 10.1186/S12995-016-0095-8.
- [21] D. Murphy and D. Hutchinson, "Is Male Rheumatoid Arthritis an Occupational Disease? A Review," *Open Rheumatol. J.*, vol. 11, no. 1, pp. 88–105, Jul. 2017, doi: 10.2174/1874312901711010088.
- [22] D. Murphy, B. James, and D. Hutchinson, "Could the significantly increased risk of rheumatoid arthritis reported in Italian male steel workers be explained by occupational exposure to cadmium?," *Journal of Occupational Medicine and Toxicology* 2016 11:1, vol. 11, no. 1, pp. 21–, May 2016, doi: 10.1186/S12995-016-0111-Z.
- [23] G. Bjørklund, M. Dadar, S. Chirumbolo, J. Aaseth, and M. Peana, "Metals, autoimmunity, and neuroendocrinology: Is there a connection?," *Environ. Res.*, vol. 187, p. 109541, Aug. 2020, doi: 10.1016/J.ENVRES.2020.109541.
- [24] N. Y. A. Hemdan, F. Emmrich, S. Faber, J. Lehmann, and U. Sack, "Alterations of Th1/Th2 reactivity by heavy metals: Possible consequences include induction of autoimmune diseases," *Ann. N. Y. Acad. Sci.*, vol. 1109, no. 1, pp. 129–137, Aug. 2007, doi: 10.1196/ANNALS.1398.015;WEBSITE:WEBSITE:NYAS PUBS;JOURNAL:JOURNAL:17496632A.
- [25] G. Fatima, A. M. Raza, N. Hadi, N. Nigam, and A. A. Mahdi, "Cadmium in Human Diseases: It's More than Just a Mere Metal," *Indian Journal of Clinical Biochemistry*, vol. 34, no. 4, pp. 371–378, Oct. 2019, doi: 10.1007/S12291-019-00839-8/METRICS.
- [26] K. S. Min, N. Iwata, N. Tetsutikawahara, S. Onosaka, and K. Tanaka, "Effect of hemolytic and iron-deficiency anemia on intestinal absorption and tissue accumulation of cadmium," *Toxicol. Lett.*, vol. 179, no. 1, pp. 48–52, Jun. 2008, doi: 10.1016/j.toxlet.2008.04.001.
- [27] M. Wiciński, G. Liczner, K. Cadelski, T. Kohnierzak, M. Nowaczewska, and B. Malinowski, "Anemia of Chronic Diseases: Wider Diagnostics—Better Treatment?," *Nutrients* 2020, Vol. 12, Page 1784, vol. 12, no. 6, p. 1784, Jun. 2020, doi: 10.3390/NU12061784.
- [28] G. Smyrnova, "Relação entre o nível de hemoglobina e a atividade da doença em pacientes com artrite reumatoide," *Rev. Bras. Reumatol.*, vol. 54, no. 6, pp. 437–440, Nov. 2014, doi: 10.1016/J.RBR.2014.06.002.
- [29] İ. Tekeoğlu, M. Z. Şahin, A. Kamanlı, and K. Nas, "The influence of zinc levels on osteoarthritis: A comprehensive review," *Nutr.*

Res. Rev., vol. 38, no. 1, pp. 282–293, Jun. 2025, doi: 10.1017/S0954422424000234.

[30] T. Frangos and W. Maret, “Zinc and Cadmium in the Aetiology and Pathogenesis of Osteoarthritis and Rheumatoid Arthritis,” *Nutrients* 2021, Vol. 13, Page 53, vol. 13, no. 1, p. 53, Dec. 2020, doi: 10.3390/NU13010053.

[31] G. Rentschler *et al.*, “Cadmium concentrations in human blood and urine are associated with polymorphisms in zinc transporter genes,” *Metallomics*, vol. 6, no. 4, pp. 885–891, Mar. 2014, doi: 10.1039/C3MT00365E.

[32] B. Chen *et al.*, “Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets,” *Signal Transduction and Targeted Therapy* 2023 9:1, vol. 9, no. 1, pp. 6–, Jan. 2024, doi: 10.1038/s41392-023-01679-y.

[33] A. H. Shankar and A. S. Prasad, “Zinc and immune function: The biological basis of altered resistance to infection,” *American Journal of Clinical Nutrition*, vol. 68, no. 2 SUPPL., 1998, doi: 10.1093/ajcn/68.2.447S.

[34] V. E. A. Honkanen *et al.*, “Plasma zinc and copper concentrations in rheumatoid arthritis: Influence of dietary factors and disease activity,” *American Journal of Clinical Nutrition*, vol. 54, no. 6, pp. 1082–1086, 1991, doi: 10.1093/ajcn/54.6.1082.

[35] S. E. Parsons and R. A. Disilvestro, “Effects of mild zinc deficiency, plus or minus an acute-phase response, on galactosamine-induced hepatitis in rats,” *Br. J. Nutr.*, vol. 72, no. 4, pp. 611–618, Oct. 1994, doi: 10.1079/bjn19940063.

[36] M. Molenda and J. Kolmas, “The Role of Zinc in Bone Tissue Health and Regeneration—a Review,” *Biol. Trace Elem. Res.*, vol. 201, no. 12, p. 5640, Dec. 2023, doi: 10.1007/s12011-023-03631-1.

[37] S. Ala, M. Shokrzadeh, A. M. Pur Shoja, and S. S. Saeedi Saravi, “Zinc and copper plasma concentrations in rheumatoid

arthritis patients from a selected population in Iran,” *Pak. J. Biol. Sci.*, vol. 12, no. 14, pp. 1041–1044, 2009, doi: 10.3923/PJBS.2009.1041.1044.

[38] H. S. Al-, A. Msc, A. H. Al-Hashimi, H. S. Al-Ali, and N. I. Al-Edani, “T T H H E E M M E E D D I I C C A A L L J J O O U U R R N N A A L L O O F F B B A A S S R R A A H H U U N N I I V V E E R R S S I I T T Y Y C C L I N I C A L L E V A L U A T I O N O F Z I N C T H E R A P Y I N R H E U M A T O I D A R T H R I T I S”.

[39] E. Rajaei, K. Mowla, A. Ghorbani, M. Dargahi-Malamir, M. Zarei, and F. A. Rahimikhan, “The relationship between serum zinc levels and rheumatoid arthritis activity,” *Front. Biol. (Beijing)*, vol. 13, no. 1, p. 51, Mar. 2018, doi: 10.1007/s11515-017-1474-y.

[40] Z. Ullah, M. I. Ullah, S. Hussain, H. Kaul, and K. P. Lone, “Determination of Serum Trace Elements (Zn, Cu, and Fe) in Pakistani Patients with Rheumatoid Arthritis,” *Biol. Trace Elem. Res.*, vol. 175, no. 1, pp. 10–16, Jan. 2017, doi: 10.1007/s12011-016-0746-8.

[41] H. M. Ali and M. A. Al-Zubaidi, “Evaluation of Trace Elements in Iraqi Patients with Rheumatoid Arthritis by using Atomic Absorption Spectrophotometer (AAS),” *Iraqi Journal of Pharmaceutical Sciences*, vol. 21, no. 2, pp. 77–84, Mar. 2012, doi: 10.31351/vol21iss2pp77-84.

[42] M. Sahebari *et al.*, “Serum Trace Element Concentrations in Rheumatoid Arthritis,” *Biol. Trace Elem. Res.*, vol. 171, no. 2, pp. 237–245, Jun. 2016, doi: 10.1007/s12011-015-0501-6.

[43] Y. Y. Farid, A. K. Mohammed, and I. S. Mohammed, “Zn levels in RA patients ...,” *Farid et al Iraqi Journal of Medical Sciences*, vol. 49.

[44] P. Stolt *et al.*, “Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases,” *Ann.*

*Rheum. Dis.*, vol. 62, no. 9, pp. 835–841, Sep. 2003, doi: 10.1136/ard.62.9.835.

[45] C. G. Elinder, L. Friberg, B. Lind, and M. Jawaaid, “Lead and cadmium levels in blood samples from the general population of Sweden,” *Environ. Res.*, vol. 30, no. 1, pp. 233–253, Feb. 1983, doi: 10.1016/0013-9351(83)90183-4.

[46] H. I. Afridi, T. G. Kazi, D. Brabazon, and S. Naher, “Interaction between zinc,

cadmium, and lead in scalp hair samples of Pakistani and Irish smokers rheumatoid arthritis subjects in relation to controls,” *Biol. Trace Elem. Res.*, vol. 148, no. 2, pp. 139–147, Aug. 2012, doi: 10.1007/s12011-012-9352-6.

[47] M. M. Ansari, Neha, and H. A. Khan, “Effect of cadmium chloride exposure during the induction of collagen induced arthritis,” *Chem. Biol. Interact.*, vol. 238, pp. 55–65, Jun. 2015, doi: 10.1016/j.cbi.2015.06.001.